Stem Cell Therapies for Treatment of Discogenic Low Back Pain: a Comprehensive Review
Purpose of Review
Discogenic low back pain (DLBP) stems from pathology in one or more intervertebral discs identified as the root cause of the pain. It is the most common type of chronic low back pain (LBP), representing 26–42% of attributable cases.
The clinical presentation of DLBP includes increased pain when sitting, coughing, or sneezing, and experiencing relief when standing or ambulating. Dermatomal radiation of pain to the lower extremity and neurological symptoms including numbness, motor weakness, and urinary or fecal incontinence are signs of advanced disease with disc prolapse, nerve root compression, or spinal stenosis. Degenerative disc disease is caused by both a decrease in disc nutrient supply causing decreased oxygen, lowered pH, and lessened ability of the intervertebral disc (IVD) to respond to increased load or injury; moreover, changes in the extracellular matrix composition cause weakening of the tissue and skewing the extracellular matrix’s (ECM) harmonious balance between catabolic and anabolic factors for cell turnover in favor of catabolism. Thus, the degeneration of the disc causes a shift from type II to type I collagen expression by NP cells and a decrease in aggrecan synthesis leads to dehydrated matrix cells ultimately with loss of swelling pressure needed for mechanical support. Cell-based therapies such as autologous nucleus pulposus cell re-implantation have in animal models and human trials shown improvements in LBP score, retention of hydration in IVD, and increased disc height. Percutaneously delivered multipotent mesenchymal stem cell (MSC) therapy has been proposed as a potential means to uniquely ameliorate discogenic LBP holistically through three mechanisms: mitigation of primary nociceptive disc pain, slow or reversal of the catabolic metabolism, and restoration of disc tissue. Embryonic stem cells (ESCs) can differentiate into cells of all three germ layers in vitro, but their use is hindered related to ethical concerns, potential for immune rejection after transplantation, disease, and teratoma formation. Another similar approach to treating back pain is transplantation of the nucleus pulposus, which, like stem cell therapy, seeks to address the underlying cause of intervertebral disc degeneration by aiming to reverse the destructive inflammatory process and regenerate the proteoglycans and collagen found in healthy disc tissue.
Preliminary animal models and clinical studies have shown mesenchymal stem cell implantation as a potential therapy for IVD regeneration and ECM restoration via a shift towards favorable anabolic balance and reduction of pain.
KeywordsLow back pain Mesenchymal stem cells Embryonic stem cells Degenerative disc disease Discogenic pain Nucleus pulposus transplantation
Compliance with Ethical Standards
Conflict of Interest
Ivan Urits, Alexander Capuco, Medha Sharma, Omar Viswanath, Elyse M. Cornett, and Vwaire Orhurhu declare no conflict of interest. Alan D. Kaye discloses that he is on the Speakers Bureau for Depomed, Inc. and Merck.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ 2017;356:i6748.Google Scholar
- 4.Longo UG, Loppini M, Denaro L, Maffulli N, Denaro V. Rating scales for low back pain. Br Med Bull Oxford University Press; 2010;94:81–144.Google Scholar
- 16.• Chou R, Qaseem A, Snow V, Casey D, Cross JT, Shekelle P, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med American College of Physicians; 2007;147:478. Clinical recommendations by the American Pain Society and American College of Physicians for the diagnosis and treatment of low back pain PubMedCrossRefGoogle Scholar
- 17.•Chou R, Qaseem A, Owens DK, Shekelle P. Clinical Guidelines Committee of the American College of Physicians. Diagnostic imaging for low back pain: advice for high-value health care from the American College of Physicians. Ann Intern Med. 2011;154:181–9. Clinical recommendations by the American College of Physicians for the diagnosis of low back pain.PubMedCrossRefGoogle Scholar
- 21.Zhang Y, Guo T, Guo X, Wu S. Clinical diagnosis for discogenic low back pain. Int J Biol Sci 2009;5:647–58.Google Scholar
- 22.Peng B-G. Pathophysiology, diagnosis, and treatment of discogenic low back pain. World J Orthop. 2013;4:42. Available from: http://www.wjgnet.com/2218-5836/full/v4/i2/42.htm-52. Accessed 1 Mar 2019.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Yrjama M, Tervonen O, Vanharanta H. Ultrasonic imaging of lumbar discs combined with vibration pain provocation compared with discography in the diagnosis of internal anular fissures of the lumbar spine. Spine (Phila Pa 1976). 1996.Google Scholar
- 34.Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics. 2005;5:3226–45.PubMedCrossRefGoogle Scholar
- 38.• Liu X, Krishnamoorthy D, Lin L, Xue P, Zhang F, Chi L, et al. A method for characterising human intervertebral disc glycosaminoglycan disaccharides using liquid chromatography-mass spectrometry with multiple reaction monitoring. Eur Cell Mater. 2018;35:117–31.PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Manchikanti L, Singh V. Evaluation of the relative contributions of various structures in chronic low back pain. Pain Physician. 2001;Google Scholar
- 45.•• Kumar H, Ha D-H, Lee E-J, Park JH, Shim JH, Ahn T-K, et al. Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Res Ther. 2017;8:262 Long-term follow-up of intradiscal implantation of mesenchymal stem cells for chronic low back pain.PubMedPubMedCentralCrossRefGoogle Scholar
- 54.Sivakamasundari V, Lufkin T. Stemming the degeneration: IVD stem cells and stem cell regenerative therapy for degenerative disc disease. Adv stem cells. 2013;2013.Google Scholar
- 57.Wakao S, Kuroda Y, Ogura F, Shigemoto T, Dezawa M, Wakao S, et al. Regenerative effects of mesenchymal stem cells: contribution of muse cells, a novel pluripotent stem cell type that resides in mesenchymal cells. Cells Multidisciplinary Digital Publishing Institute; 2012;1:1045–60.PubMedPubMedCentralCrossRefGoogle Scholar
- 62.Feng G, Zhao X, Liu H, Zhang H, Chen X, Shi R, et al. Transplantation of mesenchymal stem cells and nucleus pulposus cells in a degenerative disc model in rabbits: a comparison of 2 cell types as potential candidates for disc regeneration. J Neurosurg Spine. 2011;14:322–9.PubMedCrossRefGoogle Scholar
- 70.•• Teixeira GQ, Pereira CL, Ferreira JR, Maia AF, Gomez-Lazaro M, Barbosa MA, et al. Immunomodulation of human mesenchymal stem/stromal cells in intervertebral disc degeneration. Spine (Phila Pa 1976). 2018;43:E673–82 An investigation of immunomodulation to improve the efficacy of stem cell implantation.CrossRefGoogle Scholar
- 72.Wang W, Wang Y, Deng G, Ma J, Huang X, Yu J, et al. Transplantation of hypoxic-preconditioned bone mesenchymal stem cells retards intervertebral disc degeneration via enhancing implanted cell survival and migration in rats. Stem Cells Int Hindawi; 2018;2018:1–13.Google Scholar
- 76.Steffen F, Smolders LA, Roentgen AM, Bertolo A, Stoyanov J. Bone marrow-derived mesenchymal stem cells as autologous therapy in dogs with naturally occurring intervertebral disc disease: feasibility, safety, and preliminary results. Tissue Eng Part C Methods. 2017;23:643–51.PubMedCrossRefGoogle Scholar
- 82.Elabd C, Centeno CJ, Schultz JR, Lutz G, Ichim T, Silva FJ. Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study. J Transl Med BioMed Central; 2016;14:1–9.Google Scholar
- 83.Centeno C, Markle J, Dodson E, Stemper I, Williams CJ, Hyzy M, et al. Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. J Transl Med BioMed Central; 2017;15:1–12.Google Scholar
- 85.•• Perez-Cruet M, Beeravolu N, McKee C, Brougham J, Khan I, Bakshi S, et al. Potential of human nucleus pulposus-like cells derived from umbilical cord to treat degenerative disc disease. Neurosurgery. 2018;0:1–12 An investigation of umbilical cord derived nucleus pulposus like cells for the treatmentof degenerative disc disease.Google Scholar